Amicus Therapeutics reported third‑quarter 2025 revenue of $169.1 million, a 17 % increase at constant exchange rates from the $141.5 million reported for the same period in 2024.
GAAP net income for the quarter was $17.3 million, giving a GAAP earnings per share of $0.06. The company’s GAAP EPS beat the consensus estimate of $0.03 and the lower estimate of $0.05, but fell short of the $0.12 consensus figure reported by some analysts.
Cash, cash equivalents and marketable securities increased by $32.8 million to $263.8 million, reflecting a stronger liquidity position than the $230.9 million reported in Q2 2025.
Revenue growth was driven by strong sales of Galafold, which grew 15 % year‑over‑year to $138.3 million, and by a 45 % increase in sales of Pombiliti and Opfolda to $30.7 million. Galafold maintained a 69 % market share among treated Fabry patients with amenable mutations.
Amicus reiterated its full‑year 2025 guidance, projecting total revenue growth of 15‑22 % and positive GAAP net income for the second half of the year. The company highlighted continued demand for its rare‑disease therapies and its plans to expand its commercial footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.